share_log

Mangoceuticals | 8-K: Current report

SEC ·  Aug 15 21:27

Summary by Futu AI

On August 15, 2024, Mangoceuticals, Inc., also known as MangoRx, reported substantial growth in its financial results for the first half of 2024. The company, which specializes in men's health and wellness products, including treatments for erectile dysfunction, hair growth, weight loss, and hormone replacement therapies, disclosed a 1,685% increase in shareholders' equity and a 56% increase in year-over-year revenue. Shareholders' equity surged to $13.8 million, up from $774,754 at the end of the previous year, largely due to the acquisition of a patent portfolio from Intramont Technologies. Revenue for the six months ended June 30, 2024, reached $377,258, with a gross profit of $217,190, marking significant growth from the same period in the previous year. CEO Jacob Cohen highlighted the company's focus on innovation and customer...Show More
On August 15, 2024, Mangoceuticals, Inc., also known as MangoRx, reported substantial growth in its financial results for the first half of 2024. The company, which specializes in men's health and wellness products, including treatments for erectile dysfunction, hair growth, weight loss, and hormone replacement therapies, disclosed a 1,685% increase in shareholders' equity and a 56% increase in year-over-year revenue. Shareholders' equity surged to $13.8 million, up from $774,754 at the end of the previous year, largely due to the acquisition of a patent portfolio from Intramont Technologies. Revenue for the six months ended June 30, 2024, reached $377,258, with a gross profit of $217,190, marking significant growth from the same period in the previous year. CEO Jacob Cohen highlighted the company's focus on innovation and customer satisfaction, with expectations for continued growth in the latter half of the year. MangoRx is also preparing to launch new products, including compounded oral dissolvable tablet (ODT) GLP-1 inhibitors for weight loss and a hormone therapy product for low testosterone. The company's telemedicine platform facilitates the prescription and delivery of its products directly to consumers.

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.